Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Net Margin (2016 - 2025)

Heron Therapeutics' Net Margin history spans 12 years, with the latest figure at 0.09% for Q4 2025.

  • For Q4 2025, Net Margin fell 1014.0% year-over-year to 0.09%; the TTM value through Dec 2025 reached 1.64%, up 635.0%, while the annual FY2025 figure was 6.58%, 313.0% up from the prior year.
  • Net Margin reached 0.09% in Q4 2025 per HRTX's latest filing, up from 10.71% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 10.23% in Q4 2024 to a low of 269.43% in Q2 2021.
  • Average Net Margin over 5 years is 104.04%, with a median of 73.55% recorded in 2022.
  • Peak YoY movement for Net Margin: plummeted -5272bps in 2021, then soared 19141bps in 2022.
  • A 5-year view of Net Margin shows it stood at 259.2% in 2021, then surged by 74bps to 67.79% in 2022, then surged by 56bps to 29.85% in 2023, then skyrocketed by 134bps to 10.23% in 2024, then plummeted by -99bps to 0.09% in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Net Margin are 0.09% (Q4 2025), 10.71% (Q3 2025), and 4.4% (Q2 2025).